<DOC>
	<DOCNO>NCT00187005</DOCNO>
	<brief_summary>The main purpose study find radiation central nervous system ( CNS ) safely omit early intensification chemotherapy chemotherapy give directly CNS . Another purpose find survival child ALL improve risk-directed therapy give protocol .</brief_summary>
	<brief_title>Total Therapy Study XIV Newly Diagnosed Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>There multiple secondary objective trial : - To estimate overall event-free survival patient treat risk-directed therapy - To identify plasma methotrexate ( MTX ) concentration produce maximum intracellular accumulation active metabolite ( methotrexate polyglutamates , MTXPG ) vivo , relation major cell lineage genotype - To determine relation MTXPG accumulation leukemic lymphoblast antileukemic effect , measure inhibition de novo purine synthesis , decrease circulate blast 4 day initiation single-agent high-dose methotrexate treatment - To determine plasma MTX concentration exceed require maximum MTXPG accumulation cause paradoxical decrease accumulation long-chain MTXPG lymphoblast , ( e.g. , due `` feedback inhibition '' folypolyglutamate synthetase ) - To determine significant difference lymphoblast uptake MTX expression reduce folate carrier T-lineage v B-lineage lymphoblast , hyperdiploid vs non-hyperdiploid B-lineage lymphoblast - To investigate whether atovaquone ( ATQ ) effective trimethoprim-sulfamethoxazole ( TMP-SMZ ) prevent Pneumocystis carinii pneumonitis ( PCP ) - To investigate whether administration G-CSF onset febrile episode neutropenia patient induction two reinductions affect extent duration fever . - To determine whether level minimal residual disease peripheral blood ( PB ) reflect measure bone marrow ( BM ) immunologic molecular technique - To assess degree DNA damage somatic cell ( leukocyte ) treatment - To explore whether genetic polymorphism enzymes important metabolism antileukemic agent ( e.g . methylene tetrahydrofolate reductase , thiopurine methyltransferase , glutathione transferase ) correlate MTX pharmacology lymphoblast , acute toxicity long-term outcome - To explore whether development anti-asparaginase antibody CSF depletion asparaginase correlate acute toxicity long-term outcome - To assess relation MRI change brain ( especially white matter abnormality ) HDMTX intrathecal treatment , neurologic cognitive deficit , CSF level homocysteines diminish quality life - To investigate whether early MRI change relate late MRI abnormality , neurologic cognitive deficit , diminish quality life - To correlate change MRI , neurologic cognitive deficit diminish quality life select pharmacokinetic variable - To determine prevalence low bone density correlate complication potential risk factor Details Treatment Interventions : Treatment consist three main phase , Remission Induction ( include Upfront HDMTX Window ) , Consolidation , Continuation . Window Therapy Upfront HDMTX consider first part remission induction treatment . HDMTX give vein 24 hour ( one day ) . MTX 500 mg/m2 standard risk 250 mg/m2 low-risk case give 1 hour , follow immediately maintenance infusion ( 4500 mg/m2 standard/high-risk 2250 mg/m2 low-risk case ) 23 hour . Remission Induction Therapy ( 6-7 week ) The remain induction treatment begin Prednisone 40 mg/m2/day PO ( tid ) Days 5-32 , Vincristine 1.5 mg/m2/week IV day 5 , 12 , 19 , 26 , Daunorubicin 25 mg/m2/week IV day 5 , 12 , L-asparaginase 10,000 U/m2/dose IM ( thrice weekly ) day 6 , 8 , 10 , 12 , 14 , 16 ( 19 , 21 , 23 ) , triple intrathecal treatment , follow Etoposide 300 mg/m2/dose IV 2 hr day 26 , 29 , 33 , plus Cytarabine 300 mg/m2/dose IV 2 hr Days 26 , 29 , 33 . Triple intrathecal chemotherapy ( MHA ) use remain treatment dosage base age Frequency total number triple intrathecal treatment Remission Induction base patient 's risk CNS relapse . Consolidation ( 2 week ) Patients receive High dose Methotrexate ( HDMTX ) 2.5 gm/m2 ( low-risk ) 5 gm/m2 ( standard-or-high-risk ) IV 24 hr day 1 8 6-Mercaptopurine 25 mg/m2/day PO day 1 14 . All patient receive triple intrathecal therapy weekly two dos Days 1 8 . Continuation treatment ( 120 week girls 146 week boys ) Post-remission continuation treatment begin 7 day second course HDMTX consolidation treatment , provide ANC ≥300/mm3 platelet count ≥ 50 x 109/L . Continuation treatment 120 week girls 146 week boys differs accord risk classification . Reinduction Treatment This phase treatment start week 12 28 bone marrow examination confirm complete remission . Reinduction treatment give twice : Weeks 12 16 week 28 32 standard/high risk case ; week 12 15 week 28-31 low-risk case . Leucovorin rescue ( 5 mg/m2 ) give 24 30 hour intrathecal treatment remission reinduction treatment . No chemotherapy give week 16 32 standard/high risk patient . Standard- High-Risk Leukemia - DEX ( dexamethasone ) 8 mg/m2 PO daily ( tid ) x 7 day VCR ( vincristine ) 1.5 mg/m2 IV push ( max . 2 mg ) give week 1 , 5 , 9 , 17 , 21 , 25 , 33 , 37 , 41 , 45 , 49 , 53 , 57 , 61 , 65 , 69 , 73 , 77 , 81 , 85 , 89 , 93 , 97 , 101 , 105 , 109 , 113 , 117 . - VP16 ( etoposide ) 300 mg/m2 IV 2 hour CTX ( cyclophosphamide ) 300 mg/m2 IV short infusion give week 2 , 6 , 10 , 18 , 22 , 26 , 34 , 38 , 42 , 46 , 50 , 54 , 58 , 62 , 66 , 70 , 74 , 78 , 82 , 86 , 90 , 94 . - 6MP ( 6-mercaptopurine ) 75 mg/m2 PO daily x 7 day MTX ( methotrexate ) 40 mg/m2 IV IM week 3 , 8 , 11 , 19 , 24 , 27 , 35 , 39 , 40 , 43 , 47 , 48 , 51 , 55 , 56 , 59 , 63 , 64 , 67 , 71 , 72 , 75 , 79 , 80 , 83 , 87 , 88 , 91 , 95 , 96 , 98 , 99 , 102 , 103 , 104 , 106 , 107 , 110 , 111 , 112 , 114 , 115 , 118 , 119 , 120 , week 121-146 boy . - MTX ( methotrexate ) 40 mg/m2 IV IM Ara-C ( cytarabine ) 300 mg/m2 IV push give weeks4 , 20 , 36 , 44 , 52 , 60 , 68 , 76 , 84 , 92 , 100 , 108 , 116 . - 6MP ( 6-mercaptopurine ) 75 mg/m2 PO daily x 7 day HDMTX 5 gm/ gm/m2 give week 7 23 . - HDMTX 5 gm/ gm/m2 Ara-C ( cytarabine ) 300 mg/m2 IV push give week 15 31 . Reinduction Treatment-Standard/High Risk - DEX ( dexamethasone ) 8 mg/m2 PO daily ( tid ) day 1-21 , - VCR ( vincristine ) 1.5 mg/m2/week IV ( max . 2 mg ) day 1 , 8 , 15 - PEG-asparaginase 2500 U/m2/week IM week 28-31 , day 8 , 15 - Idarubicin 5 mg/m2/week IV day 1 8 - HDMTX 5 gm/m2 IV day 22 - ITMHA ( methotrexate+hydrocortisone+ara-C ) , age dependent , IT day 1 - High-dose cytarabine 2 gm/m2 IV q 12 hr Days 23 , 24 Low Risk - 6MP ( 6-mercaptopurine ) 75 mg/m2 PO daily x 7 day MTX ( methotrexate ) 40 mg/m2 IV IM week 1 , 2 , 3 , 4 , 6 , 8 , 10 , , 11 , 16 , 18- 20 , 22 , 24 , 26 , 27 , 32 , 34- 36 , 38-40 , 42- 44 , 46-48 , 50-52 , 54-56 , 58-60 , 62-64 , 66-68 , 70-72 , 74-76 , 78-80 , 82-84 , 86-88 , 90-92 , 94-96 , 98-100 , 102-104 , 106-108 , 110-112 , 114-116 , 118-120 week 121-146 boy . - 6MP ( 6-mercaptopurine ) 75 mg/m2 PO daily x 7 day , MTX ( methotrexate ) 40 mg/m2 IV IM , DEX ( dexamethasone ) 8 mg/m2 PO daily ( tid ) x 7 day VCR ( vincristine ) 1.5 mg/m2 IV push ( max . 2 mg ) week 5 , 9 , 17 , 21 , 25 , 33 , 37 , 41 , 45 , 49 , 53 , 57 , 61 , 65 , 69 , 73 , 77 , 81 , 85 , 89 , 93 , 97 , 101 , 105 , 109 , 113 , 117 . - 6MP ( 6-mercaptopurine ) 75 mg/m2 PO daily x 7 day HDMTX 2.5 gm/m2 week 7 , 15 , 23 31 . Reinduction Treatment-Low Risk - DEX ( dexamethasone ) 8 mg/m2 PO daily day 1-21 , - VCR ( vincristine ) 1.5 mg/m2/week IV push ( max . 2 mg ) day 1 , 8 , 15 - PEG-asparaginase 2500 U/m2/week IM day 8 , 15 - Idarubicin 5 mg/m2/week IV day 1 - HDMTX 2.5 gm/m2 day 22 - ITMHA ( methotrexate+hydrocortisone+ara-C ) , age dependent , IT day 1 22 - 6 MP 75 mg/m2/day PO day 22-28 IT Chemotherapy - Triple intrathecal treatment give low-risk case CNS-1 status week 1 , 2 , 7 , 12 , 15 , 23 , 28 , 31 , 39 , 47 , 54 . - Triple intrathecal treatment give low-risk case CNS-2 traumatic CSF status week 1 , 2 , 7 , 12 , 15 , 19 , 23 , 28 , 31 , 36 , 39 , 43 , 47 , 54 . - Triple intrathecal treatment give standard/high-risk case week 1 , 2 , 7 , 12 , 19 , 23 , 28 , 36 , 39 , 43 , 47 , 54 . - Triple intrathecal treatment give standard/high-risk case WBC ≥100 x 109/L , T-cell ALL WBC ≥50 x 109/L , presence Philadelphia chromosome , MLL rearrangement , near haploidy , CNS-3 status week 1 , 2 , 7 , 12 , 19 , 23 , 28 , 36 , 39 , 43 , 47 , 54 , 64 , 72 , 80 , 88 . Hematopoietic Stem Cell Transplantation Patients meet criteria high-risk ALL offer option transplantation match , relate unrelated donor . However , option decline suitable donor available , patient remain study continue receive chemotherapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnosis nonBcell leukemia immunophenotyping ( e.g . Tcell , Bcell precursor , acute undifferentiated leukemia ) Ages less equal 18 year age One week less prior therapy , limited glucocorticoid , vinca alkaloid , emergency radiation therapy mediastinum one dose intrathecal chemotherapy Exclusion Criteria Participants great 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Leukemia</keyword>
</DOC>